Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Mangoceuticals, Inc. (MGRX) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▲ Bullish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Top 35% of 5172 stocks scored
Rank correlation · 90D -26.0% Spearman, 316 dates
Market Cap $7M small-cap · #11 of 13 peers
Summary

Mangoceuticals, Inc. (MGRX) stock forecast summary

Our AI ranks Mangoceuticals, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Mangoceuticals, Inc. is a small-cap company with a market capitalization of $7M. It ranks number 11 by market capitalization among the 13 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast. Its Net Margin of -6539.3% is the lowest of the 10 peers that report one. Its Current Ratio of 0.18x is the lowest of the 11 peers that report one.

For MGRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -26.0%, measured on 316 forecast dates between 2023-05-12 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -28.0%, measured on 359 forecast dates between 2023-05-12 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, MGRX included.

Follow MGRX free
Price

MGRX price chart and AI forecast

MGRX
Cross-section · 2026-10-16

How MGRX ranks among 5172 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Mangoceuticals, Inc. (MGRX) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.

Valuation & Market

MetricMGRXIndustry medianRank
Market Cap $7M $91M 11/13
P/B Ratio 0.55x 2.51x 8/9
EPS $-1.35 – –
Book Value/Share $0.58 – –

Profitability & Margins

MetricMGRXIndustry medianRank
ROE -159.3% 10.1% 7/7
ROA -140.8% 4.8% 8/9
ROIC -132.8% 10.6% 8/8
Gross Margin 70.2% 56.2% 2/6
Operating Margin -5562.1% 0.6% 8/9
Net Margin -6539.3% 4.8% 10/10
EBT Margin -5817.7% 1.4% 9/10

Financial Health

MetricMGRXIndustry medianRank
Current Ratio 0.18x 1.13x 11/11
D/E Ratio 0.13x 0.55x 9/10
Financial Leverage 1.13x 1.53x 8/9
Working Capital -$1M $6M 9/11

Cash Flow

MetricMGRXIndustry medianRank
Operating Cash Flow -$4M $3M 7/10

Income Statement

MetricMGRXIndustry medianRank
Operating Income -$17M $190K 8/9
Net Income -$20M $8M 9/10
Cost of Goods Sold $40K $12M 6/7

Dividend & Shareholder Information

MetricMGRXIndustry medianRank
Shares Outstanding 22M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$250K1.8% of assets
Cash & Short-term Investments$230K1.6% of assets
Total Liabilities$2M11.6% of assets
Quarterly Financial Reports

MGRX quarterly financials and insider trading

Industry Peers · Services-Misc Health & Allied Services, NEC

Mangoceuticals, Inc. (MGRX) industry peers

Companies classified under the same SEC industry code as Mangoceuticals, Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
MGRX Mangoceuticals, Inc. ▲ $7M – 0.6x
FMS Fresenius Medical Care Ag ▼ $12.85B – –
DVA Davita Inc. ▶ $11.95B 15.4x –
SHC Sotera Health Co ▼ $5.11B 41.6x 7.7x
PGNY Progyny, Inc. ▼ $2.06B 33.6x 4.6x
AGL Agilon Health, Inc. ▲ $1.43B – 6.3x
VMD Viemed Healthcare, Inc. ▼ $361M 26.3x 2.5x
PARK Park Dental Partners, Inc. ▲ $91M – 3.1x
MRAI Marpai, Inc. ▶ $85M – –
CCEL Cryo Cell International Inc ▲ $29M – –
PFHO Pacific Health Care Organization Inc ▲ $12M 10.4x 0.9x
NIVF Newgenivf Group Ltd ▼ $2M – 0.1x
BRTX Biorestorative Therapies, Inc. ▶ $2M – 0.6x

Where MGRX sits on the market map

Industrial Applications and Services · Services-Misc Health & Allied Services, NEC
Explore the map →
News

Mangoceuticals, Inc. (MGRX) stock news

More news available

Sign up free to read all 10 news articles and stay updated on market developments.

Sign Up Free to Read More
FAQ

Mangoceuticals, Inc. (MGRX) stock forecast FAQ

What is the Mangoceuticals, Inc. (MGRX) stock forecast?

Our AI ranks Mangoceuticals, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Mangoceuticals, Inc. stock predictions?

For MGRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -26.0%, measured on 316 forecast dates between 2023-05-12 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -28.0%, measured on 359 forecast dates between 2023-05-12 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Mangoceuticals, Inc. forecasts updated?

Mangoceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Mangoceuticals, Inc.'s industry peers?

13 issuers in our coverage, MGRX included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Fresenius Medical Care Ag (FMS), Davita Inc. (DVA), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.